Jack L. Wyszomierski
Known title: DirectorCIK: 0001023225
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 10, 2026
Deutsche Bank downgrades SITE, cuts target to $91. Deutsche Bank downgraded SiteOne Landscape Supply to Hold and reduced its price target to $91. RBC Capital kept an Outperform rating but also trimmed its target to $124, while the average analyst target remains around $123. The downgrade and target cuts arrive as the stock has been falling, trading near a support level of $96.66, and the company announced its third‑quarter 2026 earnings release date.
Transaction History
| EXEL | ▼ Sell | Open Market | 3,925 | $198K | 6/1/2026 | View on chart |
| EXEL | ▲ Buy | Grant | 8,367 | $0 | 5/27/2026 | View on chart |
| SITE | ▲ Buy | Grant | 1,186 | $0 | 5/13/2026 | View on chart |
| EXEL | ▲ Buy | Option Exercise | 20,634 | $408K | 2/18/2026 | View on chart |
| EXEL | ▼ Sell | Open Market | 99,574 | $4.4M | 2/18/2026 | View on chart |
| EXEL | ▼ Sell | Open Market | 7,535 | $325K | 6/3/2025 | View on chart |
| EXEL | ▲ Buy | Grant | 9,812 | $0 | 5/29/2025 | View on chart |
| SITE | ▲ Buy | Grant | 1,125 | $0 | 5/14/2025 | View on chart |
| EXEL | ▲ Buy | Option Exercise | 15,874 | $325K | 2/28/2025 | View on chart |
| EXEL | ▼ Sell | Open Market | 8,768 | $331K | 2/28/2025 | View on chart |
| EXEL | ▼ Sell | Open Market | 8,287 | $182K | 6/4/2024 | View on chart |
| EXEL | ▲ Buy | Grant | 18,838 | $0 | 5/31/2024 | View on chart |
| EXEL | ▲ Buy | Option Exercise | 11,686 | $229K | 5/13/2024 | View on chart |
| EXEL | ▼ Sell | Open Market | 10,923 | $233K | 5/13/2024 | View on chart |
| SITE | ▲ Buy | Grant | 865 | $0 | 5/7/2024 | View on chart |
| EXEL | ▲ Buy | Grant | 20,718 | $0 | 6/1/2023 | View on chart |
| SITE | ▲ Buy | Grant | 878 | $0 | 5/11/2023 | View on chart |
| EXEL | ▲ Buy | Option Exercise | 40,000 | $252K | 3/10/2023 | View on chart |
| EXEL | ▼ Sell | Open Market | 15,300 | $254K | 3/10/2023 | View on chart |
| EXEL | ▲ Buy | Grant | 19,575 | $0 | 5/26/2022 | View on chart |
| SITE | ▲ Buy | Grant | 960 | $0 | 5/11/2022 | View on chart |
| EXEL | ▲ Buy | Option Exercise | 40,000 | $125K | 4/4/2022 | View on chart |
| EXEL | ▼ Sell | Open Market | 6,696 | $154K | 4/4/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 4, 2026
Exelixis Shares Rise on CABOMETYX Revenue
Exelixis stock has moved higher following reports of strong revenue from its drug CABOMETYX. This performance is relevant as it demonstrates the commercial strength of the company's primary product. The FDA also expanded the label for Merck's Welireg, a competitor in the kidney cancer space, which adds context to the market environment.
Exelixis Shares Rise on CABOMETYX Revenue. Exelixis stock has moved higher following reports of strong revenue from its drug CABOMETYX. This performance is relevant as it demonstrates the commercial strength of the company's primary product. The FDA also expanded the label for Merck's Welireg, a competitor in the kidney cancer space, which adds context to the market environment.